Office Of New Drugs Oversight Of Advisory Committees Creates Bias – Graham
Executive Summary
The Office of New Drugs' authority over FDA advisory committees creates a bias in industry's favor, Office of Drug Safety Associate Director for Science David Graham said March 21 during a National Press Club "Newsmakers" conference in Washington, D.C
You may also be interested in...
FDA Safety Act Calls For “Expedited Procedures” For Drug Withdrawals
Postmarketing safety legislation proposed by Senate Finance Committee Chairman Charles Grassley (R-Iowa) and Sen. Chris Dodd (D-Conn.) calls for FDA to establish "expedited procedures" for drug withdrawals
FDA Safety Act Calls For “Expedited Procedures” For Drug Withdrawals
Postmarketing safety legislation proposed by Senate Finance Committee Chairman Charles Grassley (R-Iowa) and Sen. Chris Dodd (D-Conn.) calls for FDA to establish "expedited procedures" for drug withdrawals
FDA’s Crawford Open To Discussing Independent Drug Safety Office
FDA Acting Commissioner Lester Crawford is willing to consider making the Office of Drug Safety formally independent from drug review activities if he is confirmed as the agency's permanent leader